Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CircuLite Inc.

This article was originally published in Start Up

Executive Summary

More than 80% of the ventricular assist devices in development today use an open surgical approach. CircuLite Inc. is developing a completely interventional VAD. With its percutaneous device, the company aims to extend treatment to patients at an earlier stage of heart failure, thus halting--or perhaps reversing--disease progression.
Advertisement

Related Content

CircuLite: Partial Support Enables Patient Management
CircuLite: Partial Support Enables Patient Management
Cardiac Assist: Pumping up the Heart Failure Market
Berlin Heart: Starting Over
Interventional Heart Failure
Cardiak Ltd.
Cardiak Ltd.
ATI: Is This the Model for Device Development?
ATI: Is This the Model for Device Development?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT037438

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel